Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (NCT04484623)

🧪 Interventions in This Study

• Belantamab mafodotin (DRUG)
• Pomalidomide (DRUG)
• Dexamethasone (DRUG)
• Bortezomib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (122 Sites)

Showing the first 25 of 122 sites.

• GSK Investigational Site — Tucson, Arizona
• GSK Investigational Site — Fort Myers, Florida
• GSK Investigational Site — Boston, Massachusetts
• GSK Investigational Site — Kansas City, Missouri
• GSK Investigational Site — Nashville, Tennessee
• GSK Investigational Site — Garran, Australian Capital Territory
• GSK Investigational Site — Darlinghurst, New South Wales
• GSK Investigational Site — Gosford NSW, New South Wales
• GSK Investigational Site — Port Macquarie, New South Wales
• GSK Investigational Site — Benowa, Queensland
• GSK Investigational Site — South Brisbane, Queensland
• GSK Investigational Site — Adelaide, South Australia
• GSK Investigational Site — Fitzroy, Victoria
• GSK Investigational Site — Heidelberg, Victoria
• GSK Investigational Site — Malvern, Victoria
• GSK Investigational Site — Nedlands, Western Australia
• GSK Investigational Site — Porto Alegre, Rio Grande do Sul
• GSK Investigational Site — Curitiba,
• GSK Investigational Site — Joinville,
• GSK Investigational Site — São Paulo,
• GSK Investigational Site — Beijing,
• GSK Investigational Site — Beijing,
• GSK Investigational Site — Changchun,
• GSK Investigational Site — Changsha,
• GSK Investigational Site — Guangzhou,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.